skip to main content
Idioma:

Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals

177 Paola Sterpetti ; Marucci, Luca ; Candelaresi, Cinzia ; Toksoz, Deniz

American journal of physiology: Gastrointestinal and liver physiology, 2006-04, Vol.53 (4), p.G624 [Revista revisada por pares]

Bethesda: American Physiological Society

Texto completo disponible

Citas Citado por
  • Título:
    Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals
  • Autor: 177 Paola Sterpetti ; Marucci, Luca ; Candelaresi, Cinzia ; Toksoz, Deniz
  • Materias: Drug resistance ; Enzymes ; Oncology ; Skin cancer
  • Es parte de: American journal of physiology: Gastrointestinal and liver physiology, 2006-04, Vol.53 (4), p.G624
  • Descripción: Hepatocellular carcinoma is highly resistant to chemotherapeutic agents, thus the need to discover effective therapeutic molecules to suppress cancer cell growth and to overcome drug resistance is urgent. The Rho GTPase is implicated in cancer and metastasis and is directly activated by the Lymphoid blast crisis (Lbc) protooncogene, a Rho guanine-nucleotide exchange factor. The aim of the study was to analyze the expression of Lbc in hepatocarcinoma and to determine the effect of Lbc-induced Rho signaling on expression, growth rate and resistance to genotoxic stress. We found, by immunohistochemical analysis of biopsy samples and Northern and Western blot analyses of cell lines, that Lbc is absent in normal adult liver but is abundantly expressed in hepatocarcinoma, implying an increased Rho pathway signaling. Lbc stably transfected hepatocarcinoma cells exhibit increased proliferation and levels of ERK and cyclin D1 activation, which are blocked by a Rho inhibitor. In contrast, AKT activation was not altered. Moreover, Lbc expression confers increased resistance to genotoxic stress induced by doxorubicin, which is associated with upregulation of Bcl-2 and BAD phosphorylation, and this is reversed by a Rho inhibitor. In conclusion, these data support a role for Rho in liver cancer progression and resistance to therapy and may provide a basis for developing effective treatment for hepatocarcinoma. [PUBLICATION ABSTRACT]
  • Editor: Bethesda: American Physiological Society
  • Idioma: Inglés
Volver a la lista de resultados
Ir a la página anteriorAnterior Resultado  6 SiguienteIr a la siguiente página

  • Realización: ABCD-USP USP   Logos de Redes Sociales: Freepik

Buscando en bases de datos remotas, por favor espere

  • Buscando por
  • enscope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
  • Mostrar lo que tiene hasta ahora